Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention

Abciximab is a widely studied glycoprotein IIb/IIIa inhibitor, specifically in the setting of patients undergoing percutaneous coronary intervention (PCI). The populations studied have included patients with non-ST-segment acute coronary syndromes, ST-segment elevation myocardial infarction, and ele...

Descripción completa

Detalles Bibliográficos
Autores principales: Vergara-Jimenez, Jennifer, Tricoci, Pierluigi
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2835553/
https://www.ncbi.nlm.nih.gov/pubmed/20234778

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2835553/
https://www.ncbi.nlm.nih.gov/pubmed/20234778

Ejemplares similares